Probiotics: insights and new opportunities for Clostridioides difficile intervention.
Crit Rev Microbiol
; 49(3): 414-434, 2023 May.
Article
en En
| MEDLINE
| ID: mdl-35574602
ABSTRACT
Clostridioides difficile infection (CDI) is a life-threatening disease caused by the Gram-positive, opportunistic intestinal pathogen C. difficile. Despite the availability of antimicrobial drugs to treat CDI, such as vancomycin, metronidazole, and fidaxomicin, recurrence of infection remains a significant clinical challenge. The use of live commensal microorganisms, or probiotics, is one of the most investigated non-antibiotic therapeutic options to balance gastrointestinal (GI) microbiota and subsequently tackle dysbiosis. In this review, we will discuss major commensal probiotic strains that have the potential to prevent and/or treat CDI and its recurrence, reassess the efficacy of probiotics supplementation as a CDI intervention, delve into lessons learned from probiotic modulation of the immune system, explore avenues like genome-scale metabolic network reconstructions, genome sequencing, and multi-omics to identify novel strains and understand their functionality, and discuss the current regulatory framework, challenges, and future directions.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Clostridioides difficile
/
Infecciones por Clostridium
/
Probióticos
Límite:
Humans
Idioma:
En
Revista:
Crit Rev Microbiol
Asunto de la revista:
MICROBIOLOGIA
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos